Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Diurnal Group stock price, quote, forecast and news

DNL.L
GB00BDB6Q760

Price

0.27
Today +/-
+0
Today %
+0 %
P

Diurnal Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Diurnal Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Diurnal Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Diurnal Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Diurnal Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Diurnal Group Stock Price History

DateDiurnal Group Price
11/1/20220.27 undefined
10/31/20220.27 undefined

Diurnal Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Diurnal Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Diurnal Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Diurnal Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Diurnal Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Diurnal Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Diurnal Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Diurnal Group’s growth potential.

Diurnal Group Revenue, EBIT and net profit per share

DateDiurnal Group RevenueDiurnal Group EBITDiurnal Group Net Income
2026e37.73 M undefined-16.96 M undefined-19.22 M undefined
2025e28.43 M undefined-12.71 M undefined-18.27 M undefined
2024e17.7 M undefined-9.81 M undefined-17.88 M undefined
2023e9.82 M undefined-16.83 M undefined-19.58 M undefined
20224.68 M undefined-18.85 M undefined-16.57 M undefined
20214.37 M undefined-11.62 M undefined-10.05 M undefined
20206.31 M undefined-6.02 M undefined-4.07 M undefined
20191.04 M undefined-14.53 M undefined-12.29 M undefined
201873,000 undefined-16.78 M undefined-14.62 M undefined
20170 undefined-12.07 M undefined-9.43 M undefined
20160 undefined-6.99 M undefined-6.57 M undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined-880,000 undefined-860,000 undefined

Diurnal Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20132014201520162017201820192020202120222023e2024e2025e2026e
00000016449172837
-------500.00-33.33-125.0088.8964.7132.14
-------83.3375.0075.00----
00000005330000
000-6-12-16-14-6-11-18-16-9-12-16
-------1,400.00-100.00-275.00-450.00-177.78-52.94-42.86-43.24
000-6-9-14-12-4-10-16-19-17-18-19
----50.0055.56-14.29-66.67150.0060.0018.75-10.535.885.56
52.710044.2152.7955.1862.4695.33137.09169.180000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Diurnal Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Diurnal Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2013201420152016201720182019202020212022
                   
0.560.956.0730.1119.8817.289.1515.4335.0116.49
000000.080.510.390.366.17
000003.112.571.563.12.38
000000.120.671.241.631.36
0.030.080.080.350.711.90.480.581.460
0.591.036.1530.4620.5922.513.3819.2141.5526.4
100531826332314816
00000001.6700
0000000000
2010106416497992184
0000000000
0000000000
0.030.010.020.010.020.040.081.770.240.2
0.621.046.1730.4720.6122.5413.4620.9841.7926.6
                   
0.440.440.062.612.623.074.236.088.48.49
3.093.0912.3523.6323.6837.7742.1550.9777.4177.46
-3.05-3.85-6.37-0.31-9.22-23.96-35.44-38.66-48.25-64.42
0000000000
0000000000
0.48-0.326.0425.9317.0816.8810.9418.3837.5621.53
0.080.090.270.241.723.162.52.561.735.04
0.030.030.131.211.552.42002.20
000366581002400
0000000000
2020240000000
0.130.140.421.483.345.662.52.564.165.04
0.051.0403.243.5100000
0000000000
0230000016366332
0.051.2703.243.5100.020.040.060.03
0.181.410.424.726.855.662.522.594.235.08
0.661.096.4630.6523.9322.5413.4620.9841.7926.6
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Diurnal Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Diurnal Group's financial health and stability.

Assets

Diurnal Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Diurnal Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Diurnal Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Diurnal Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2013201420152016201720182019202020212022
00-2-6-9-14-12-4-10-16
0000000000
0000000000
0001130100
0000-2-1-1-20-2
0000000000
00000-2-2-2-1-1
00-2-5-10-12-13-4-10-18
0000000000
000-133110000
000-133110000
0000000000
0104000000
1082409510280
1172909510280
----------
0000000000
00510-78-8618-17
-0.79-0.79-2.86-5.06-10.49-12.8-13.8-4.85-10.83-18.9
0000000000

Diurnal Group stock margins

The Diurnal Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Diurnal Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Diurnal Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Diurnal Group's sales revenue. A higher gross margin percentage indicates that the Diurnal Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Diurnal Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Diurnal Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Diurnal Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Diurnal Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Diurnal Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Diurnal Group Margin History

Diurnal Group Gross marginDiurnal Group Profit marginDiurnal Group EBIT marginDiurnal Group Profit margin
2026e78.16 %-44.95 %-50.93 %
2025e78.16 %-44.7 %-64.26 %
2024e78.16 %-55.41 %-101.06 %
2023e78.16 %-171.37 %-199.39 %
202278.16 %-402.35 %-353.76 %
202182.18 %-265.73 %-229.9 %
202089.42 %-95.34 %-64.5 %
201978.54 %-1,391.38 %-1,177.01 %
201879.45 %-22,984.93 %-20,031.51 %
201778.16 %0 %0 %
201678.16 %0 %0 %
201578.16 %0 %0 %
201478.16 %0 %0 %
201378.16 %0 %0 %

Diurnal Group Stock Sales Revenue, EBIT, Earnings per Share

The Diurnal Group earnings per share therefore indicates how much revenue Diurnal Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Diurnal Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Diurnal Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Diurnal Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Diurnal Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Diurnal Group Revenue, EBIT and net profit per share

DateDiurnal Group Sales per ShareDiurnal Group EBIT per shareDiurnal Group Earnings per Share
2026e0.22 undefined0 undefined-0.11 undefined
2025e0.17 undefined0 undefined-0.11 undefined
2024e0.1 undefined0 undefined-0.11 undefined
2023e0.06 undefined0 undefined-0.12 undefined
20220.03 undefined-0.11 undefined-0.1 undefined
20210.03 undefined-0.08 undefined-0.07 undefined
20200.07 undefined-0.06 undefined-0.04 undefined
20190.02 undefined-0.23 undefined-0.2 undefined
20180 undefined-0.3 undefined-0.27 undefined
20170 undefined-0.23 undefined-0.18 undefined
20160 undefined-0.16 undefined-0.15 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined-0.02 undefined-0.02 undefined

Diurnal Group business model

The Diurnal Group PLC is a British company specializing in the development and marketing of innovative hormone therapies. It was founded in 2004 by Martin Whitaker and Richard Ross, both experienced experts in the field of hormone research. The idea behind Diurnal was to develop therapies that support the body in releasing hormones according to a natural rhythm. This is particularly important for patients with endocrine disorders such as Addison's disease, a rare but serious hormone deficiency syndrome. Diurnal's business model is based on the development and marketing of hormone therapies that support the body's natural rhythm. Over the years, the company has developed a wide range of products tailored to individual patient needs. Included in Diurnal's product range are various therapies for the treatment of endocrine disorders. One of the most well-known products is the drug Chronocort, used in the treatment of Addison's disease. Chronocort is a unique immediate-release formulation of hydrocortisone that mimics the release of cortisol, thus supporting the body's natural rhythm. Another important product of Diurnal is Infacort, a hydrocortisone preparation for the treatment of children with Addison's disease. Infacort is a specially developed microgranulated formulation that allows for precise dosing and facilitates the treatment of children. In addition to these two products, Diurnal is working on the development of other hormone therapies, including a drug for the treatment of diseases such as adrenocortical carcinoma, an aggressive cancer affecting the adrenal glands. Diurnal is headquartered in Cardiff, Wales, and has production facilities in Europe and Asia. The company has experienced impressive growth in recent years and has already conducted several successful clinical trials. Diurnal is a company dedicated to the development and marketing of innovative hormone therapies. With a wide range of products and a strong presence in the European market, the company has become an important player in endocrinology. Diurnal Group is one of the most popular companies on Eulerpool.com.

Diurnal Group SWOT Analysis

Strengths

Diurnal Group PLC has a strong portfolio of innovative hormonal drugs, which provide effective treatment options for patients with rare endocrine disorders.

The company possesses a dedicated and experienced research and development team, enabling it to continually develop and enhance its product offerings.

Diurnal Group PLC has established strategic partnerships with key pharmaceutical companies, helping to expand its market reach and distribution capabilities.

Weaknesses

The company heavily relies on a limited number of products for its revenue generation, which may expose it to significant risk in case of regulatory issues or market competition.

Diurnal Group PLC faces challenges in terms of scaling up its manufacturing and production capabilities to meet increasing demand for its drugs.

The company's geographic presence is currently limited, which could impede its potential for growth in untapped markets.

Opportunities

There is a growing global prevalence of endocrine disorders, presenting a significant market opportunity for Diurnal Group PLC to expand its customer base.

Advancements in technology and healthcare infrastructure provide an opportunity for the company to streamline its supply chain and improve operational efficiency.

Diurnal Group PLC could explore collaborations with academic institutions or research organizations to further enhance its research and development capabilities.

Threats

Increased competition from existing pharmaceutical companies and potential new entrants in the market may impact the company's market share and pricing power.

Uncertainties surrounding the regulatory environment for pharmaceuticals can pose challenges and delays in obtaining necessary approvals for product development and commercialization.

Economic downturns and fluctuations in currency exchange rates can impact Diurnal Group PLC's financial performance, particularly for international operations.

Diurnal Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Diurnal Group historical P/E ratio, EBIT, and P/S ratio.

Diurnal Group shares outstanding

The number of shares was Diurnal Group in 2023 — This indicates how many shares 169.182 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Diurnal Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Diurnal Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Diurnal Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Diurnal Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Diurnal Group.

Diurnal Group list of shareholders

%
Name
Stocks
Change
Date
6.79643 % Development Bank of Wales Plc11,534,88809/9/2022
5.74477 % Chelverton Asset Management Ltd.9,750,00008/30/2022
5.17702 % Amati Global Investors Limited8,786,429-713,5718/31/2022
4.96996 % J O Hambro Capital Management Limited8,435,000-65,0001/6/2022
4.61265 % BGF Investment Management Limited7,828,571285,7148/30/2022
3.83663 % Oddo BHF Asset Management S.A.S6,511,5204,430,0009/15/2022
29.40159 % IP Group PLC49,900,28509/7/2022
2.48014 % BNP Paribas Asset Management France SAS4,209,2844,209,2848/31/2022
2.30380 % Milne (Alexander)3,910,0001,450,0009/9/2022
11.78414 % Polar Capital LLP20,000,0001,327,6278/30/2022
1
2
3
4
...
5

Most common questions regarding Diurnal Group

What values and corporate philosophy does Diurnal Group represent?

Diurnal Group PLC represents a set of core values and corporate philosophy that drive its operations. The company believes in integrity, transparency, and accountability in all its endeavors. Diurnal Group PLC is dedicated to delivering innovative and effective solutions in the field of hormone therapeutics, aiming to improve the lives of patients suffering from endocrine disorders. With a strong emphasis on research and development, the company strives to maintain a high level of scientific excellence and continuously evolve its product portfolio. Diurnal Group PLC's commitment to patient-centricity and collaboration with healthcare professionals reflects its vision of providing optimal and accessible treatments worldwide.

In which countries and regions is Diurnal Group primarily present?

Diurnal Group PLC is primarily present in the United Kingdom and Europe.

What significant milestones has the company Diurnal Group achieved?

Diurnal Group PLC has achieved several significant milestones. Firstly, the company successfully received marketing authorization in Europe for its hormone replacement therapy, Alkindi. This milestone allowed Diurnal Group PLC to launch Alkindi and provide treatment for pediatric patients with adrenal insufficiency. Additionally, the company achieved a positive outcome in the European decentralized procedure for its product, Chronocort, which is used to treat adrenal insufficiency in adults. These milestones demonstrate Diurnal Group PLC's successful development and commercialization of innovative therapies that address unmet medical needs in endocrinology.

What is the history and background of the company Diurnal Group?

Diurnal Group PLC is a pharmaceutical company founded in 2004 and headquartered in the United Kingdom. It specializes in developing and commercializing hormone-based therapeutics to treat rare and chronic endocrine diseases. Diurnal Group PLC focuses on innovative oral formulations, aiming to provide patients with convenient and effective treatment options. With a strong emphasis on research and development, the company has successfully brought several products to market, addressing significant unmet medical needs. Diurnal Group PLC continues to expand its portfolio and collaborate with healthcare professionals, aiming to improve the quality of life for patients suffering from hormonal disorders.

Who are the main competitors of Diurnal Group in the market?

The main competitors of Diurnal Group PLC in the market include pharmaceutical companies that operate in the field of specialty pharmaceuticals and endocrinology. Some key competitors of Diurnal Group PLC are pharmaceutical companies such as Novartis AG, Sanofi SA, and Pfizer Inc., among others. These companies also focus on developing and commercializing drugs in areas related to endocrinology, allowing for a competitive environment within the market.

In which industries is Diurnal Group primarily active?

Diurnal Group PLC primarily operates in the pharmaceutical industry.

What is the business model of Diurnal Group?

Diurnal Group PLC operates in the pharmaceutical industry, specializing in rare and chronic endocrine diseases. The company focuses on developing and commercializing innovative hormone-based therapies. Diurnal Group PLC aims to provide long-acting, low-dose, and convenient treatment options to improve patients' quality of life. With a strong commitment to research and development, the company combines its expertise in endocrinology, formulation science, and regulatory affairs to bring novel treatments to market. With a focus on unmet medical needs, Diurnal Group PLC strives to make a significant impact in the field of endocrinology.

What is the P/E ratio of Diurnal Group 2024?

The Diurnal Group P/E ratio is -2.58.

What is the P/S ratio of Diurnal Group 2024?

The Diurnal Group P/S ratio is 2.61.

What is the AlleAktien quality score of Diurnal Group?

The AlleAktien quality score for Diurnal Group is 4/10.

What is the revenue of Diurnal Group 2024?

The expected Diurnal Group revenue is 17.7 M GBP.

How high is the profit of Diurnal Group 2024?

The expected Diurnal Group profit is -17.88 M GBP.

What is the business model of Diurnal Group

The Diurnal Group PLC is a specialized pharmaceutical company based in the UK, focusing on the development and marketing of hormone preparations for the treatment of rare and chronic diseases and disorders. The company is divided into different areas: - Endocrinology: This is Diurnal's main area, focusing on the treatment of hormonal disorders. The most well-known product in this area is Alkindi, a cortisone preparation for the treatment of adrenal insufficiencies in children. In addition to Alkindi, the company also offers Chronocort, which is used to treat adult patients with Addison's disease, and Infacort, which is specifically developed for infants and young children. - Chronobiology: This area focuses on the development of drugs targeting the sleep-wake cycle and other periodic rhythms of the human body. In this area, the company has already developed two products; Chronocort to alleviate symptoms of Cushing's syndrome, and Infacort, intended for the treatment of adrenal insufficiency in newborns. - Metabolism: Diurnal aims to develop new treatment options for patients with metabolism disorders such as hypoglycemia and hyperammonemia. The company works closely with clinicians and other medical professionals to understand and meet the needs of patients. Diurnal's goal is to offer innovative drugs that can improve patients' lives and alleviate their symptoms. Diurnal also utilizes state-of-the-art technologies and research findings to enhance the quality and efficacy of its products. The company has the potential to make decades-long contributions through its broad range of activities in various areas of endocrinology. Overall, the company's business model is focused on addressing the needs of patients with rare diseases. Diurnal is working hard to develop novel medications for the treatment of metabolism and hormone disorders that have the potential to have a life-changing impact on many people. The Diurnal Group PLC has set its goal to develop and bring to market new medications through long-term research and partnerships with clinicians and patient groups. Through this approach and their groundbreaking innovations, they have gained a reputation as a pioneer in the field of endocrinology.

What is the Diurnal Group dividend?

Diurnal Group pays a dividend of 0 GBP distributed over payouts per year.

How often does Diurnal Group pay dividends?

The dividend cannot currently be calculated for Diurnal Group or the company does not pay out a dividend.

What is the Diurnal Group ISIN?

The ISIN of Diurnal Group is GB00BDB6Q760.

What is the Diurnal Group ticker?

The ticker of Diurnal Group is DNL.L.

How much dividend does Diurnal Group pay?

Over the past 12 months, Diurnal Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diurnal Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of Diurnal Group?

The current dividend yield of Diurnal Group is .

When does Diurnal Group pay dividends?

Diurnal Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Diurnal Group?

Diurnal Group paid dividends every year for the past 0 years.

What is the dividend of Diurnal Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Diurnal Group located?

Diurnal Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Diurnal Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Diurnal Group from 9/13/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Diurnal Group pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Diurnal Group in the year 2023?

In the year 2023, Diurnal Group distributed 0 GBP as dividends.

In which currency does Diurnal Group pay out the dividend?

The dividends of Diurnal Group are distributed in GBP.

All fundamentals about Diurnal Group

Our stock analysis for Diurnal Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Diurnal Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.